HLB lost ₩121.3bn in the first half on only ₩46.7bn of revenue. HLB Co., Ltd. (KRX:028300) is valued at ₩4.4tn because investors focus on rivoceranib, not current operations. The gap between those two realities defines the risk.
Rivoceranib may still create substantial value if the US regulatory path clears. The Food and Drug Administration has previously rejected the liver-cancer application over manufacturing and inspection findings. Meanwhile, HLB keeps funding development through convertible debt. Optionality is real, but it is not free.
Second-quarter revenue reached ₩28.0bn. The prior-year quarter produced ₩15.7bn. First-quarter revenue was ₩18.7bn, slightly above ₩17.7bn one year earlier.
The first-half total of ₩46.7bn is an improvement. It remains tiny beside the company's market value. HLB's existing revenue comes from a collection of health and related businesses, not a commercial rivoceranib franchise.
Gross profit reached ₩21.4bn for the half. Selling, general and administrative expense was ₩67.1bn. That gap produced an operating loss of ₩45.7bn.
The comparable first half generated a ₩51.8bn operating loss. Operations improved by a modest amount. They did not approach break-even.
Losses became much larger below the operating line. Finance costs reached ₩21.1bn in the first quarter and ₩40.5bn in the second. Pretax loss totaled ₩121.0bn.
Net loss was ₩40.9bn in the first quarter. It widened to ₩80.4bn in the second. Equity fell from ₩493.9bn in March to ₩422.4bn by June.
The annual history shows that this isn't a new condition. HLB has reported an operating loss in every year shown since 2015. The latest annual operating loss was ₩104.2bn.
Revenue has also been unstable. It reached ₩179.7bn in 2022, then fell to ₩42.9bn in 2023. It recovered to ₩68.1bn in 2024 and ₩84.2bn in 2025.
No ordinary sales multiple can bridge current revenue to ₩4.4tn. Investors are paying for a drug outcome and the assets around it.
Rivoceranib is HLB's central asset. The company has pursued US approval for liver cancer in combination with a Chinese partner's immunotherapy. This links HLB's value to a specific regulatory result.
The Food and Drug Administration, or FDA, reviews drug safety, effectiveness and manufacturing readiness. A rejection tied to manufacturing or inspections can leave clinical efficacy arguments intact. It still prevents approval until the cited deficiencies are resolved.
That distinction creates the optimistic case. If the problems are operational rather than clinical, a corrected submission may keep the commercial thesis alive. The supplied context does not include a new FDA decision or an approval date.
The uncertainty is still binary. Investors cannot observe commercial revenue before approval. They also cannot assume a partner's manufacturing corrections will satisfy inspectors.
HLB's current accounts offer little downside support if the process takes longer. The existing business generates revenue, but it continues to lose money. Intangible assets stood at ₩353.1bn in June, which also depends on expected future benefits.
This is why normal valuation language can mislead. HLB has no positive earnings multiple. Its market value reflects probability, timing and potential drug economics that do not appear in current revenue.
The right question isn't whether ₩32,800 looks low relative to the 52-week high. The right question is how much cash and dilution may be required before the regulatory uncertainty clears.
HLB approved a new privately placed convertible bond on August 5. The face amount is ₩30.0bn. The company allocated all proceeds to operating funds for drug research, clinical work and commercialization.
The bond carries a 1% coupon and a 4% yield to maturity. It matures on August 19, 2029. Bondholders can seek early repayment starting in February 2028 under the disclosed terms.
The initial conversion price was ₩33,361 per share. Full conversion would create 899,253 shares. That is modest beside the current share count, but it is not the company's only convertible instrument.
Another ₩30.0bn bond already faced a conversion-price adjustment in late August. The separate 40th series had its price reduced after a market decline. It moved from ₩41,575 to ₩36,514.
The number of shares available on conversion rose from 721,587 to 821,602. Korean convertible bonds often include reset clauses that lower the conversion price when the listed share price falls. A lower price gives bondholders more shares for the same principal.
This mechanism protects the lender and shifts more dilution risk to existing shareholders. The adjustment was automatic under the contract. It did not require a new board decision.
The new bond extends funding, but ₩30.0bn is small relative to recent losses. First-half operating cash outflow was ₩45.0bn. Net loss exceeded the bond's face value by more than four times.
Financing cash flow was positive ₩19.7bn for the half. HLB has repeatedly depended on financing inflows because operations consume cash. That pattern is common in development-stage biotechnology, but HLB's listed value makes the stakes much larger.
Cash was ₩26.4bn at the end of June. Current assets totaled ₩101.6bn. Current liabilities were ₩397.6bn.
Those figures do not mean every liability is immediately payable in cash. They do show that near-term obligations exceed liquid operating assets by a wide margin.
Total liabilities reached ₩485.5bn in June. They had been ₩435.8bn at the end of 2025. Equity declined to ₩422.4bn from ₩494.4bn.
Operating cash outflow continued in both quarters. It was ₩17.7bn in the first quarter and ₩27.3bn in the second. The existing revenue base does not fund development.
Capital expenditure isn't the main drain. Property and equipment purchases totaled less than ₩1.0bn for the half. Losses and working capital matter more than factory investment.
The company's market capitalisation was ₩4.4 trillion at Thursday's close. The shares ended September 3 at ₩32,800. Their annual trading range is ₩25,650 to ₩68,200.
Market value is more than ten times June equity. Book value may understate a successful drug, but the premium has little support from cash or current profit.
The lower share price also makes conversion terms more relevant. One existing bond has already reset its conversion price. Further equity-linked funding may create more shares if the regulatory timeline extends.
The obvious risk is another regulatory setback. Manufacturing and inspection issues may sound narrower than clinical failure. They can still delay commercialization and require partner action outside HLB's direct control.
Timing matters because cash burn continues during every delay. Research, clinical and commercialization spending does not stop while regulators review a submission. The new bond explicitly funds those uses.
Commercial risk follows approval risk. Even an approval would not guarantee rapid adoption or profitable pricing. The financial data contain no commercial sales forecast, so the size of that opportunity remains outside this analysis.
Partner dependence adds another layer. The liver-cancer application combines rivoceranib with another company's immunotherapy. Manufacturing readiness across the combination may require coordination.
Financing can also compound downside. Reset clauses may increase conversion shares after price declines. Put options can create repayment needs if bondholders do not convert.
The existing businesses provide limited protection. First-half revenue grew, but the operating loss remained ₩45.7bn. Finance costs then made the net loss much worse.
The most useful next evidence will not be another share-price move. Investors need a formal regulatory update that identifies the status of manufacturing and inspections. They also need the next cash balance and financing schedule.
HLB's value can change sharply if rivoceranib clears the FDA. That possibility explains why current earnings are not the main valuation tool. It does not eliminate arithmetic. A ₩121.3bn half-year loss and recurring convertible funding determine how much of the future drug value may remain for current shareholders.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.